Clinical Report: ACP puts hormone therapy first for menopause symptoms
Overview
The American College of Physicians recommends hormone therapy as the first-line treatment for menopausal vasomotor symptoms, based on high-certainty evidence supporting the efficacy of estrogen alone or combined with progestogen.
Background
Menopausal vasomotor symptoms significantly impact quality of life for many women. The recent guidelines from the American College of Physicians provide a structured approach to treatment options.
Data Highlights
No numerical data provided in the source material.
Key Findings
- The ACP recommends estrogen therapy as first-line treatment for menopausal vasomotor symptoms.
- Estrogen combined with progestogen is advised for patients with a uterus, while estrogen alone is recommended for those without.
- Second-line options include desvenlafaxine or venlafaxine for patients intolerant to estrogen therapy.
- Gabapentin and neurokinin receptor antagonists are considered third-line treatments.
- High-dose estrogen is more effective than low-dose for symptom reduction.
- Evidence on the risks associated with different estrogen administration routes remains insufficient.
Clinical Implications
Clinicians should inquire about vasomotor symptoms directly. Treatment efficacy should be evaluated after 8 to 12 weeks.
Conclusion
The ACP's guidelines provide a framework for managing menopausal vasomotor symptoms.
Related Resources & Content
- American College of Physicians, Annals of Internal Medicine, 2026 -- ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms
- ASCO Publications — Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
- ASCO Publications — Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
- Associated Press Health — A look at nonhormonal options for menopause symptoms
- ASCO Publications — Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy
- A look at nonhormonal options for menopause symptoms
- ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms | ACP Online
- https://healthquality.va.gov/HEALTHQUALITY/guidelines/WH/menopause/Menopause-CPG_2026-Guideline_v1_20260930.pdf
- Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
